Drug
ABX-EGF
ABX-EGF is a pharmaceutical drug with 5 clinical trials. Historical success rate of 100.0%.
Total Trials
5
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 5 completed trials
Completion Rate
100%(5/5)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_2
5
100%
Phase Distribution
0
Early Stage
5
Mid Stage
0
Late Stage
Phase Distribution5 total trials
Phase 2Efficacy & side effects
5(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
100.0%
5 of 5 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
5
all time
Status Distribution
Completed(5)
Detailed Status
Completed5
Development Timeline
Analytics
Development Status
Total Trials
5
Active
0
Success Rate
100.0%
Most Advanced
Phase 2
Trials by Phase
Phase 25 (100.0%)
Trials by Status
completed5100%
Recent Activity
0 active trials
Showing 5 of 5
completedphase_2
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00111774
completedphase_2
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
NCT00113776
completedphase_2
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00101920
completedphase_2
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00034346
completedphase_2
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
NCT00061126
Clinical Trials (5)
Showing 5 of 5 trials
NCT00111774Phase 2
Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma
NCT00113776Phase 2
Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer
NCT00101920Phase 2
ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00034346Phase 2
ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)
NCT00061126Phase 2
ABX-EGF (a Monoclonal Antibody) Given to Patients With Prostate Cancer With or Without Tumor in Other Parts of the Body
All 5 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 5